Forward Pharma GmbH   Report issue

For profit Phase 3
Founded: Copenhagen Denmark (2005)
Status: Acquired by Biogen-IDEC (2017)

Organization Overview

First Clinical Trial
2010
NCT01230138
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (2)

dimethyl fumarate (tecfidera) (2 trials)

fumarate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Psoriasis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2